# Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations

> **NCT02982889** · PHASE1 · COMPLETED · sponsor: **Liquidia Technologies, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Acute Pain

## Interventions

- **DRUG:** LIQ865A bupivacaine formulation
- **DRUG:** LIQ865B bupivacaine formulation
- **DRUG:** Diluent for LIQ865
- **DRUG:** 0.5% bupivacaine hydrochoride

## Key facts

- **NCT ID:** NCT02982889
- **Lead sponsor:** Liquidia Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-05
- **Primary completion:** 2017-03-23
- **Final completion:** 2017-04-26
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02982889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02982889, "Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02982889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*